Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AMR Action Fund

- PMLiVE

EMA accepts Cubist antibiotic for review

Follows FDA priority review for ceftolozane/ tazobactam

- PMLiVE

FDA approves antibacterial skin drug Orbactiv

US regulator authorises Medicines Company's treatment for ABSSSI

UK flag

Antimicrobial resistance priority for new UK science minister

Greg Clark announces collaboration led by Medical Research Council

UK flag

UK healthcare professionals urged to say ‘no’ to antibiotics

Royal Colleges issues joint statement to members warning of antimicrobial resistance

UK flag

Pharma industry backs UK antibiotics plan

GSK and ABPI back David Cameron’s call for global action on antimicrobial resistance

- PMLiVE

UK innovation prize to support antibiotic diagnostics

Longitude Prize 2014 offers £10m to develop tool to fight antimicrobial resistance

- PMLiVE

Cubist gets green light from FDA for new antibiotic Sivextro

First drug approved under qualified infectious disease product framework

- PMLiVE

FDA fast-tracks new AstraZeneca antibiotic

Speeds up review period for AZD0914 in gonorrhoea

Sanofi reception

Sanofi forms antibiotic research partnership

Will team up with Germany’s Fraunhofer-Gesellschaft to develop naturally-derived substances

- PMLiVE

Cell wall inhibitors for bacterial infections

There are limited pipeline prospects to address this significant health issue

- PMLiVE

Cubist posts positive phase III antibiotic data

CXA-201 on track for 2014 filings

- PMLiVE

AZ strikes antibiotic deal with Singapore research unit

Deal with A*STAR to tackle antimicrobial resistance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links